(Washington, D.C.) — The Pharmaceutical Care Management Association released the following statement on the Pennsylvania Auditor General’s report, “Bringing Transparency & Accountability to Drug Pricing:” “The Pennsylvania Auditor General has released yet another biased report on pharmacy benefit managers (PBMs).
As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers in the health care system, according to policymakers and experts, will do nothing to actually
(Washington, D.C.) —The Pharmaceutical Care Management Association (PCMA) is launching a new print and digital ad campaign – “Protect the Savings” – to defend the savings that pharmacy benefit managers (PBMs) negotiate from drugmakers, and warn against the Administration’s newly
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked Members of Congress a critical question in a new op-ed published in Townhall: Congress wants
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on President Trump signing into law S. 2553/ S. 2554, the Know the Lowest Price Act of 2018 and the Patient Right to Know Drug Prices Act. “PCMA
Health care, business, political, and economic experts all agree pharmacy benefit companies deliver significant savings and play a critical role mitigating costs and supporting access to affordable, quality prescription drug coverage for employers and patients. A number of economists, academics,
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on S. 2554, the Patient Right to Know Drug Prices Act, scheduled to be marked up tomorrow in the U.S. Senate Committee on Health,
The PCMA says in a statement it supports the patient always paying the lowest cost at the pharmacy counter, whether the cash price or the copay
In case you missed it, PCMA President and CEO JC Scott joined Prime Therapeutics’ webinar Beyond the Script: PBM Hot Topics in D.C. to discuss how pharmacy benefit companies innovate and deliver value for patients. The panel was moderated by Mostafa
The evidence is clear: prescription drug rebates negotiated by pharmacy benefit companies with drug companies are not correlated with drug list prices, which are set solely by drug companies. A recent analysis using Centers for Medicare and Medicaid Services (CMS)
©2024 PCMA. All Rights Reserved.
